Curr Os
Thu, 17 May 2012 00:08:55 -0700
AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1st line Advanced RCC), will be presented on June 2 in an oral session by the principal investigator, Robert J. Motzer, M.D., attending physician, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, professor of medicine, Weill Medical ...
Wed, 16 May 2012 15:19:57 -0700
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1st line Advanced RCC), will be presented on June 2 in an oral session by the principal investigator, Robert J. Motzer, M.D., attending physician, genitourinary oncology service, Memorial Sloan-Kettering Cancer ...
Wed, 16 May 2012 15:05:45 -0700
STAINES, England & CHICAGO, Ill. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Astellas and AVEO confirm that tivozanib achieved median progression-free survival of 11.9 months in phase III first line superiority trial
Headlines for "curr os" provided by Yahoo! News